440678-43-3

Upstream product

• 64-17-5 ethanol 
• 618-27-9 hydroxy L-proline 
• 627100-73-6 ethyl (2S,4S)-1-benzyl-4-hydroxypyrrolidine-2-carboxylate 
• 142347-82-8 hydroxyproline ethyl ester hydrochloride 

Downstream Products

• 22029-01-2 cis-1-(N-benzyloxycarbonyl-glycyl)-4-hydroxy-L-proline 
• 618-27-9 hydroxy L-proline 
• 24587-32-4 cis-1-glycyl-4-hydroxy-L-proline 

Relevant academic research and scientific papers

INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF

The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

A short diastereoselective synthesis of cis-(2S,4S) and cis-(2R,4R)-4-hydroxyprolines

A concise synthesis of (2R,4R)-4-hydroxyproline (1) and (2S,4S)-4-hydroxyproline (2) has been developed in enantiomerically pure form from commercially available starting materials with excellent diastereoselectivity. The tightly bound chelation controlled transition state formed during the 5-exo-tet ring closure reaction is assumed to be the origin of high diastereoselectivity.

PROLINE DERIVATIVES USED AS PHARMACEUTICAL ACTIVE INGREDIENTS FOR THE TREATMENT OF TUMOURS

The invention relates to proline derivatives and their salts, to pharmaceutical agents containing said derivatives and to the use of said agents for treating tumours. The invention also relates to methods for producing said compounds and pharmaceutical ag